Geanne Rocha Moraes

Mrs. Geanne Rocha Moraes

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Organoids
Verified
Journal Article
Open access
PDF file
FOFlávia Cristina Matos Oliveira
Flávia Cristina Matos Oliveira
AVAnnemarie W. Y. Voorbij
Annemarie W. Y. Voorbij
EPElisa Cunha Pereira
Elisa Cunha Pereira
LALeonor M. M. Alves e Almeida
Leonor M. M. Alves e Almeida
GMGeanne Rocha Moraes
Geanne Rocha Moraes
Louis PenningLouis Penning
Louis Penning
For over 150 years, researchers have studied the (patho)physiology of the endocrine pancreas and devised treatment options for diabetes mellitus (DM). However, no cure has been developed so far. In dogs, diabetes mellitus type 1 (T1DM) is the most common presentation. Treatment consists of twice daily insulin injections, monitored by spatial blood glucose measurements. Even though dogs were instrumental in the discovery of insulin and islet transplantations, the treatment in diabetic dogs has remained unchanged for decades. Providing twice daily insulin injections is demanding for both owners and dogs and may result in hypoglycaemic events, creating the need for new treatment strategies. Novel regenerative medicine-based tools, such as improved β-cell culture protocols and artificial devices, have sparked hope for a cure. In human medicine, emerging technologies such as the transplantation of insulin-producing β-cells, generated by stem cell differentiation, with or without an encapsulation device, are currently tested in phase I/II clinical trials. As the pathogenesis of T1DM is remarkably similar between humans and dogs, novel treatment methods could be implemented in canine medicine. This review briefly summarises the physiology of the canine endocrine pancreas and the pathophysiology of canine DM before exploring current and possible future treatment options for canine DM.